BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma
NCT ID: NCT07226856
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE2
43 participants
INTERVENTIONAL
2025-12-01
2028-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment (BMS-986340, nivolumab, gemcitabine, nab-paclitaxel)
Patients receive nivolumab IV over 30 minutes and BMS-986340 IV over 60 minutes on day 1, as well as nab-paclitaxel IV over 30-40 minutes and gemcitabine IV over 30 minutes on days 1 and 15 of each cycle. Cycles repeat every 28 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients also undergo urine and blood sample collection, tissue biopsy, and CT throughout the study. Additionally, patients with known or suspected brain metastases may also undergo brain MRI throughout the study.
Biopsy Procedure
Undergo tissue biopsy
Biospecimen Collection
Undergo urine and blood sample collection
Computed Tomography
Undergo CT
Gemcitabine
Given IV
Imzokitug
Given IV
Magnetic Resonance Imaging
Undergo brain MRI
Nab-paclitaxel
Given IV
Nivolumab
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biopsy Procedure
Undergo tissue biopsy
Biospecimen Collection
Undergo urine and blood sample collection
Computed Tomography
Undergo CT
Gemcitabine
Given IV
Imzokitug
Given IV
Magnetic Resonance Imaging
Undergo brain MRI
Nab-paclitaxel
Given IV
Nivolumab
Given IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histological confirmation of pancreatic adenocarcinoma
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) v 1.1
* Initial diagnosis of metastatic or recurrent disease (per American Joint Committee on Cancer 8th Edition \[AJCC 8th edition 2018\])
* Electrocardiogram (ECG) without any clinically significant findings (QT interval corrected by Fridericia's formula (QTcF) ≤ 450 msec and no known arrhythmias) and per the investigator's assessment
* Hemoglobin ≥ 9.0 g/dL (≤ 15 days prior to registration) (transfusion to achieve this level is not permitted prior to registration)
* White blood cells (WBC) ≥ 2000/uL (≤ 15 days prior to registration)
* Absolute neutrophil count (ANC) ≥ 1500/mm\^3 (≤ 15 days prior to registration) (stable off any growth factor prior to registration)
* Platelet count ≥ 100,000/mm\^3 (≤ 15 days prior to registration) (transfusion to achieve this level is not permitted prior to registration)
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (≤ 15 days prior to registration) except in patients with documented Gilbert's syndrome, who must have a total bilirubin ≤ 3 x ULN
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 3.0 x institution's upper limit of normal (ULN) for patients with no concurrent liver metastases, OR ≤ 5.0 x institution's ULN for patients with concurrent liver metastases (≤ 15 days prior to registration)
* Prothrombin time (PT)/international normalized ratio (INR)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (≤ 15 days prior to registration) OR if patient is receiving anticoagulant therapy and INR or aPTT is within target range of therapy
* Calculated creatinine clearance ≥ 40 ml/min using the Cockcroft-Gault formula (≤ 15 days prior to registration)
* Negative pregnancy test done ≤ 8 days prior to registration, for persons of childbearing potential only
* Provide written informed consent
* Willingness to provide mandatory blood specimens for correlative research
* Willingness to provide mandatory tissue specimens for correlative research
* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Exclusion Criteria
* Pregnant persons
* Nursing persons
* Participants of childbearing potential who are unwilling to employ adequate contraception
* Failure to recover from any adverse events related to any of the following therapies received prior to registration:
* Minor surgical or interventional procedure
* Major surgical procedure other than diagnostic surgery, ≤ 28 days prior to registration
* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens
* Uncontrolled intercurrent illness including, but not limited to:
* Ongoing or active infection
* Symptomatic congestive heart failure ≤ 6 months prior to registration
* Unstable angina pectoris ≤ 6 months prior to registration
* Cardiac arrhythmia
* Coronary stenting or myocardial infarction ≤1 year prior to registration
* Dyspnea at rest due to complications of advanced malignancy or other disease that requires continuous oxygen therapy
* Psychiatric illness/social situations that would limit compliance with study requirements
* Known historical or active infection with hepatitis B, or active infection with hepatitis C (note that subjects with hepatitis C who have been clinically cured, defined as persistent absence of hepatitis C ribonucleic acid \[RNA\] detected by polymerase chain reaction \[PCR\] test in serum 12 weeks after completing antiviral treatment, are eligible for this study)
* Active infection or an unexplained fever \> 38.5°C during screening visits or on the first scheduled day of dosing (at the discretion of the investigator, subjects with tumor fever may be enrolled), which in the investigator's opinion might compromise the subject's participation in the study or affect the study outcome
* Interstitial lung disease, sarcoidosis, silicosis, idiopathic pulmonary fibrosis, pulmonary hypersensitivity pneumonitis or multiple allergies
* Peripheral artery disease (e.g. claudication, Leo Buerger's disease)
* Neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
* Known human immunodeficiency virus (HIV) positive with an acquired immune deficiency syndrome (AIDS)-defining opportunistic infection within the last year, or a current CD4 count \< 350 cells/uL. Participants with HIV are eligible if:
* They have received antiretroviral therapy for ≥ 4 weeks prior to the first dose of study treatment
* They continue on antiretroviral therapy as clinically indicated while enrolled on study
* CD4 counts and viral load are monitored per standard of care by a local health care provider
* Prior treatment of PDAC with chemotherapy in the neoadjuvant and/or adjuvant setting, except those where at least 12 months have elapsed since completion of the last dose and no persistent treatment-related toxicities are present
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
* Other active malignancy ≤ 5 years prior to registration. Participants with any of the following additional malignancies are not excluded:
* Malignancies with negligible risk of metastases or death (e.g., risk of death or metastases \< 5% at 5 years) that were treated with curative intent and have not recurred within the past 2 years prior to study day 1
* Completely resected basal cell or squamous cell skin cancers, carcinoma in situ (CIS) of the cervix, or ductal CIS of the breast
* Malignancies considered to be indolent and never required therapy (immunotherapy, chemotherapy, radiation)
* Malignancies treated with hormonal therapy alone
* History of myocardial infarction ≤ 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias
* Prior treatment of pancreatic cancer in the metastatic setting with surgery, radiotherapy, chemotherapy or investigational therapy:
* Palliative radiotherapy is permitted
* Placement of biliary stent/tube is permitted
* Documented serum albumin \< 3 g/dL ≤ 15 days prior to registration
* Known history of central nervous system (CNS) metastases
* Active, known, or suspected autoimmune disease (type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement)
* Systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalent) ≤ 14 days or other immunosuppressive medications ≤ 30 days prior to registration
* Prior therapy with anti-PD-1, anti-PD-L1, anti-CTLA-4, anti-CCR8 antibody
* Malignant disease other than that being treated in this study
* Receipt of an allogeneic tissue/solid organ transplant
* Any other clinically significant disease or comorbidity that may adversely affect the safe delivery of treatment within this trial or may limit compliance with study requirements in the opinion of the Investigator
* Known hypersensitivity to BMS-986340 or its metabolites and/or excipients and known hypersensitivity to any component of the regimens, their metabolites and/or excipients being used in the combination therapy cohorts for which the participant is being considered
* Unwillingness to follow study related procedures
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Tanios S. Bekaii-Saab, MD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Arizona
Scottsdale, Arizona, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Trials Referral Office
Role: primary
Clinical Trials Referral Office
Role: primary
Clinical Trials Referral Office
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-08032
Identifier Type: REGISTRY
Identifier Source: secondary_id
25-003418
Identifier Type: OTHER
Identifier Source: secondary_id
MC250402
Identifier Type: OTHER
Identifier Source: secondary_id
MC250402
Identifier Type: -
Identifier Source: org_study_id